Pharmaceutical

Grünenthal gains Valinor Pharma and constipation drug Movantik

Grünenthal has announced the acquisition of Valinor Pharma and its opioid-induced constipation (OIC) therapy Movantik for $250m.

Jul 24, 2024 - 04:00
Grünenthal gains Valinor Pharma and constipation drug Movantik
Grünenthal has announced the acquisition of Valinor Pharma and its opioid-induced constipation (OIC) therapy Movantik for $250m.
Read the original article

Tags:

Previous Article

Johnson & Johnson submits sNDA for SPRAVATO to treat depression

Next Article

UNAIDS boss calls on Gilead to provide ‘miracle’ drug to developing countries

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Weight-loss startup Calibrate cuts 18% of workforce as obesity drugs spark growing competition

STAT+: Weight-loss startup Calibrate cuts 18% of workfo...

Apr 15, 2023

STAT+: Top federal lobbyist at PhRMA leaves

STAT+: Top federal lobbyist at PhRMA leaves

Jun 20, 2023

Regeneron and Sonoma Biotherapeutics partner to develop T cell therapies

Regeneron and Sonoma Biotherapeutics partner to develop...

Mar 29, 2023